<DOC>
	<DOCNO>NCT00457444</DOCNO>
	<brief_summary>Primary Objective Comparison inhibition allergic response assess nasal provocation test epicutanous pollen allergen administration placebo epicutaneous administration . Secondary Objectives Comparison efficacy placebo epicutanous pollen allergen administration evaluate visual analog symptom scale ( nasal itching , sneeze , rhinorrhea , conjunctival redness , lacrimation , lung symptom ) , Comparison inhibition allergic response assess skin prick test epicutanous pollen allergen administration placebo epicutaneous administration . - Trial medicinal product</brief_summary>
	<brief_title>Study Assess Clinical Efficacy Safety Novel Method Specific Allergen Immunotherapy Grass Pollen Allergic Subjects Epicutanous Allergen Administration</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : Written inform consent History grass pollen allergic rhinitis Male female 18 year 65 year Positive skin prick test grass pollen Positive nasal provocation test Exclusion criterion : Atopic eczema history permanent Perennial allergic rhinitis Symptoms infectious disease rhinitis last 2 week Surgical intervention last 30 day Pregnancy nurse History HIV AIDS Mastocytosis ( cutaneous systemic ) Significant cardiovascular disease Hypertension ( blood pressure &gt; 160 / 95 ) Significant pulmonary , renal and/or hepatic disease Significant hematological disorder Moderate severe asthma History malignancy History neurological psychatric disease Autoimmune disease Antihistamines long halflives last week Systemic topical steroid 5 day Active infectious disease Contraindicated medication : immunosuppressive agent Betablockers ACEinhibitors Tricyclic antidepressant Daily use Betaagonists steroid inhaler Participation another clinical trial /study last 60 day Participation another clinical trial / study moment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2007</verification_date>
</DOC>